Redox systems are key players in vascular health. A shift in redox homeostasis-that results in an imbalance between reactive oxygen species (ROS) generation and endogenous antioxidant defenses has the potential to create a state of oxidative stress that subsequently plays a role in the pathogenesis of a number of diseases, including those of the cardiovascular and metabolic system. Statins, which are primarily used to reduce the concentration of low-density lipoprotein cholesterol, have also been shown to reduce oxidative stress by modulating redox systems.
Introduction
Statins,3-hydroxy-3-methylglutarylcoenzymeA (HMG-CoA) reductase inhibitors, are widely prescribedinclinicalpracticetoreducetheplasmalevels of low-density lipoprotein (LDL) cholesterol. Currently, more than 25 million individuals worldwide take statins 1) .Treatment with statins has been shown to reduce cardiovascular morbidity and mortality in many landmark clinical trials 2, 3) , and a number of studies suggest that statins have beneficial effects on thecardiovascularsystembeyondloweringLDL-cholesterol [4] [5] [6] [7] . The 2013 American Heart Association/ of these drugs in treating cardiovascular disorders as wellasotherchronicconditionsassociatedwithoxidative stress. The possible adverse effects of statins on glucose homeostasis, which may be related to the redoxsystem,arealsodiscussed.
Role of the Redox System in the Genesis of Metabolic and Cardiovascular Disorders
Redoxsignalingisanimportantprocessinavariety of cellular activities, such as cell proliferation, migration, differentiation and apoptosis [16] [17] [18] . Redox injury, as a pathological mechanism, is involved in a widerangeofpathophysiologicalprocesses,including senescence, inflammation, hypoxia and ischemia/ reperfusion 19, 20) , all of which may contribute to the progression of various diseases, from cardiovascular disorders, such as hypertension 21) and atherosclerosis 22) , to metabolic conditions, such as fatty liver 23) andtype2diabetesmellitus(T2DM) 24) .Aschematic representationoftheinterplaybetweentheredoxsystem,inflammatoryprocessesanddevelopmentofatherosclerosisisprovidedinFig. 1.
Cardiovascular Disease Lipid Oxidation and Oxidized LDL
LDL oxidation is a key player in the initiation American College of Cardiology guidelines recommendtheadministrationofhigh-intensitystatintherapyandextenditsusetoindividualsatriskofvascular disease 8) .Onepossibleeffectofstatinsistheirability to reduce reactive oxygen species (ROS) production and/oractivity,whichhasthepotentialtoinhibitthe development of atherosclerosis, independent of LDL reduction 9, 10) . In addition, several studies have demonstrated the antioxidative properties of statins 6, 11) , andithaspreviouslybeenshown,bothinvitroandin vivo, that statins inhibit lipid and lipoprotein oxidation, thereby suppressing ROS formation and/or bluntingthedamagingeffectsoftheseradicals 6, 12) . The oxidative modification of LDL particles in thevesselwallplaysacriticalroleinthedevelopment of atherosclerosis 13, 14) . Therefore, reducing oxidized LDL is a potentially effective method for mitigating the atherogenicity of LDL particles. The observed anti-inflammatory effects of statins also appear to be relatedtotheabilityofthesedrugstoblocktheproductionand/oractivityofROSandsuppresstheoxidationofLDLparticles 15) . Inthisreview,wediscusstheeffectsofstatinson redoxstateregulationfromacardiometabolicperspective, focusing on the antioxidant and anti-inflammatorypropertiesoftheseagents.Thepleiotropiceffects ofstatinshavethepotentialtoaidtheclinicalefficacy Oxygen-derived free radicals are generated by the binding of angiotensinⅡ (AngⅡ) to angiotensinⅡ typeⅠ receptor (AT1R). Oxygen-derived free radicals dissociate inhibitory factor,ⅠB and thus activate NF-κB. Activated NF-κB then stimulates the expression of proinflammatorygenesinthenucleusandproductionofvariousproinflammatorychemokinesandcytokines,allofwhichcontributetothedevelopmentofatherosclerosis. andprogressionofatherosclerosis 14) .LDLisoxidized by ROS released from circulating and vascular wall cells 25, 26) .Biochemically,LDLoxidationistheconsequenceoffreeradicaldrivenchainreactionsinwhich polyunsaturatedfattyacidsareconvertedtolipidperoxides that subsequently generate a range of biologicallyactivealdehydes 27) . Oxidatively modified LDL, or oxidized LDL, is involved in the early development of atherosclerotic lesions 14) . Several in vitro studies have shown that lipid-laden foam cells are formed after macrophages take up oxidized LDL 10, 28, 29) . In addition, the presence of lipid-laden foam cells is a typical feature of vulnerable atherosclerotic lesions.Therefore, the oxidativemodificationofLDLplaysaroleinthedevelopmentofatheroscleroticlesionsviatheformationof foamcells 13) .Recentevidenceindicatesthatmodified apolipoproteinBderivedfromoxidizedLDLaccumulates in foam cells 29) . Furthermore, macrophagederivedfoamcellscontainmanylipiddropletsinthe cytoplasm, and the levels of oxidized LDL are increased in patients with a history of acute myocardialinfarctionandcarotidarteryatherosclerosis 28, [30] [31] [32] . AlthoughtheroleofoxidizedLDLinvivoisnotcompletelyunderstood,ithasbeensuggestedthatmeasuring the level of oxidized LDL in the plasma may be helpful for predicting the incidence of cardiovascular events 28, 30) . Moreover, the presence of oxidized LDL intheLDLfractionofhumanplasmahasbeendemonstratedusingELISAassays 30, 32) .Theaccumulation of oxidized LDL in atherosclerotic lesions has also beendocumentedbasedonthefindingsofimmunohistochemicalstainingusingmonoclonalantibodies 33) .
Relationship between Inflammation and Oxidative Stress in the Setting of CVD
Inflammation is a complex process that impacts theonsetandprogressionofatherosclerosisandCVD in many different ways 34, 35) . Inflammatory markers shown to be elevated in patients with CVD include the levels of C-reactive protein, interleukin-8 (IL8), monocyte chemoattractant protein-1 (MCP1) and tumor necrosis factor-α (TNFα), all of which play a crucial role in recruiting neutrophils,T lymphocytes andmonocytestothevascularwall 36, 37) .Inaddition, increasedCD40-CD40ligandinteractionsresultina prothrombotic state 38) , while increased matrix metalloproteinasesleadtoplaquerupture 39) . Manyinflammatoryprocessesareinvolvedinthe productionandactionsofROSbyNAD(P)Hoxidase inthevascularwallcell 9) .Forexample,nuclearfactor (NF)-κB,atranscriptionfactorthatplaysakeyrolein theexpressionof proinflammatorycytokines,ispositivelyregulatedbyROS 40) .Consistentwiththisobservation, dimethyl sulfoxide (DMSO), a scavenger of ROS, inhibits the release of proinflammatory cytokines 41) ,whereasROScontributetotheformationof oxidizedLDL,whichinturnsleadstothedeposition of foam cells in atherosclerotic plaques 10) .Therefore, oxidativestressandinflammationareimportantcausative factors for atherosclerotic vascular diseases, particularlyunderconditionsofdiabetes 42) .
Diabetes Mellitus and its Complications
Oxidative stress associated with lipotoxicity has been known to contribute to the development of T2DM.Mitochondrialdysfunctionandlipidhomeostasis disruption may also play a role in the onset of insulin resistance 43) , while functional impairments in mitochondria induce adipocyte dysfunction with a subsequent increase in the circulating levels of free fatty acids (FFAs) and their abnormal deposition in pancreaticβ-cells, thus resulting in lipotoxicity and mitochondrialandpancreaticβ-celldysfunction 44, 45) . Several mechanisms have been proposed for the development of diabetic complications (Fig. 2) , including:(1)anincreaseintheactivityofthepolyol pathway, (2) an increase in the activity of the hexosamine pathway, (3) an increase in the formation of advancedglycationend-products,(4)activationofthe protein kinase C (PKC) pathway and (5) an increase in the activity of proinflammatory pathways [46] [47] [48] [49] . Of note,theoveractivationofthesepathwaysiscausedby the hyperglycemia-induced overproduction of superoxide anions by the mitochondrial electron transport chain. Since the activity of glyceraldehyde phosphate dehydrogenase(GAPDH),akeyglycolyticenzyme,is downregulated by superoxide anions, a reduction in the speed of glycolysis leads to an increase in ROS production,thusaugmentingaviciousnegativefeedbackcycle 50) . Inthiscontext,animbalanceofnicotineadenine dinucleotide(NAD＋)andNADH,itsreducedform, isakeycontributortotargetorgandamageinpatients with diabetes mellitus. NAD＋ is a coenzyme found in all living cells. NADH is abundant in the cytosol and is an important reducing agent in many enzymatic reactions 51, 52) . NAD＋/NADH is transported bycarrierssuchasthemalate-aspartateshuttle 53) .The balancebetweenNAD＋andNADHisimportantfor the regulation of the redox system in cells 54) , and NADP＋/NADPHregulatestheactivitiesofenzymes involvedinthesirtuin1,pyruvatedehydrogenaseand GAPDH pathways, all of which play a role in the onsetofdiabetesanditscomplications 45, [54] [55] [56] .Therefore,animbalanceintheredoxsystemcontributesto thedevelopmentofdiabetesmellitusanditscomplications.
Obesity and Metabolic Syndrome: Relationships between Insulin Resistance, Oxidative Stress and Inflammation Leading to CVD
Systemic oxidative stress is associated with abdominal obesity and insulin resistance 57, 58) . Along withoxidativestress,chroniclow-intensityinflammation is clinically evident in obese 59) and insulin-resistant subjects 60) , manifesting as increased levels of inflammatorybiomarkers,suchasC-reactiveprotein, TNFα,IL6andfibrinogen.
Metabolicsyndrome,definedastheclusteringof obesity, dyslipidemia, hypertension and insulin resistance 61) , is a well-known risk factor for the development of T2DM and CVD. Patients with metabolic syndromefrequentlyhavealipidprofilecharacterized by high triglyceride and low HDL-cholesterol levels withanLDLfractionthatisusuallynotincreasedin concentrationbutwhichconsistsofsmall,denseparticlesthataremoresusceptibletooxidation.Thispattern is highly atherogenic 62) . According to the CoronaryArteryRiskDevelopmentinYoungAdultsstudy, a high concentration of oxidized LDL is associated with an increased incidence of abdominal obesity, hyperglycemia, hypertriglyceridemia and metabolic syndrome 63) . In a study investigating the association between insulin resistance and lipid peroxidation, patientswithmetabolicsyndromeand/orT2DMwere foundtohaveincreasedlevelsofoxidationproductsof linoleic acid and malondialdehyde 64) . Oxidized LDL activatessmoothmusclecellsandmacrophagestoproduce gelatinase, which leads to the development of vulnerable plaques 65) . In an experimental study, preadipocytesexposedtooxidizedLDLdisplayedahigh rate of proliferation, low level of apoptosis and increasedpre-adipocytefactor-1mRNAexpression 66) . LDL 67) . The paraoxonase-1 (PON1) activity associatedwithHDLhastheabilitytoprotectLDLagainst oxidativemodification,andalowlevelofPON1isa predictive factor of multivessel involvement of the coronary arteries in patients with hyperglycemia 68) . Furthermore,thelevelofoxidizedLDLcorrelatespositively with the expression of toll-like receptor 2 and interferon regulatory factor 1, suggesting a relationshipbetweenoxidativestressandinflammationinthe processofatheroscleroticplaqueformation 69) .
Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is characterizedbytheaccumulationofintrahepatictriglyceridesunrelatedtoalcoholconsumption.NAFLD isoftenconsideredtobethehepaticmanifestationof insulin resistance. The number of individuals with NAFLD in Western countries is increasing, and the condition has become the most common cause of chronic liver disease 70) . In the large cohorts, subjects with NAFLD have been found to have an increased riskofdevelopingmetabolicsyndromeandT2DM 71, 72) . NAFLDincludesaspectrumofdisturbancesencompassingvariousdegreesofliverdamage,rangingfrom simplelipidaccumulationtonon-alcoholicsteatohepatitis(NASH),whichischaracterizedbythepresence of hepatocellular inflammation in association with fibrosis.NAFLDmayprogresstoNASHandisarisk factor for the development of CVD [73] [74] [75] as well as hepatocellularcarcinoma 76) . Oxidativestressplaysamajorroleintheonsetof NAFLD (Fig. 3) 23) . Altered reduction/oxidation reactionsgenerateROS,thusleadingtodamageofhepatocytes.Verylongandlongchainfattyacids(VLCFAs andLCFAs)areoxidizedbyperoxisomesandmetabolized as a result of microsomal oxidation. After the VLCFAs and LCFAs chains are shortened by peroxisomalandmicrosomaloxidation,theyareoxidizedin themitochondrialoxidationsystem.Underconditions of insulin resistance, an increased amount of FFAs is releasedfromadiposetissueandtakenupbytheliver. This overflow of FFAs increases ROS production as well as decreases the activity of antioxidant systems, therebyinducingoxidativestress 77) .Mitochondriaare responsible for oxidative phosphorylation and fatty acidbeta-oxidation.Theseorganellesare,inturn,the majorsourceofROSandaresusceptibletooxidative damage.The excessive generation of ROS itself may beconsideredadirecteffectofmitochondrialdysfunction 78) , which acts synergistically with inflammation in the generation of ROS, subsequently encouraging the progression from simple steatosis to NASH 79) . ROS also induce the secretion of cytokines, such as TNFα, IL8 and transforming growth factor-β (TGFβ),allofwhichplayaroleinthedevelopment ofsteatohepatitisandfibrosis 70) . TriglyceridesderivedfromcirculatingFFAsaccumulate in the liver, which may lead to the onset of inflammation mediated by CD36. CD36 and its receptor play an important role in facilitating fatty aciduptake,whichprecedesthesecretionandstorage of triglycerides 80, 81) . CD36 is also involved in the inflammatoryresponseinbothadipocytesandmacrophages associated with complications of diet-induced obesity 82) . Furthermore, insulin resistance plays an importantroleintherelationshipbetweentriglyceride accumulation and inflammation 83, 84) , as triglyceride accumulation in the liver aggravates hepatic insulin resistance, which subsequently induces low-grade inflammation 85) .Thisseriesofeventsultimatelycontributestothedevelopmentofsteatohepatitis (Fig. 3) .
Taken together, the pathogenesis of NAFLD is not yet fully understood; however, accumulated data suggestthatoxidativestressandanalteredredoxbalanceplaycriticalrolesintheonsetofNAFLDandits progressionfromsteatosistosteatohepatitis.
Role of Statins in the Redox System from a Cardiovascular and Metabolic Perspective
Statin therapy decreases cholesterol synthesis by inhibiting3-hydroxy-3-methylglutarylCoAreductase, whichsubsequentlyincreasestheactivityoftheLDL receptoranddecreasestheconcentrationofLDL-cholesterolintheplasma.Inmanylargetrials,treatment withstatinshasbeenshowntodecreasecardiovascular morbidity and mortality by reducing LDL [86] [87] [88] [89] [90] . In additiontotheirLDL-loweringactions,statinspossess antioxidant and anti-inflammatory properties that may contribute to their cardioprotective effects [91] [92] [93] . Therefore,itisimportanttoconsidertheroleplayed bythepleiotropiceffectsofstatinsinthemanagement ofcardiovascularandmetabolicdisorders.Thevarious beneficialeffectsofstatinsareshowninFig. 4.
Role of the Antioxidant and Anti-Inflammatory Effects of Statins in Treating CVD
A number of studies have demonstrated that statins directly inhibit LDL-cholesterol oxidation. In addition, LDL-cholesterol isolated from patients treatedwithsimvastatinhasbeenfoundtobeprotectiveagainstLDLoxidation 94) ,whilefluvastatininhibitsLDLoxidation 95) andpreferentiallyscavengesradicals directly 96) . Interestingly, a direct comparison betweenfluvastatinandpravastatinfoundthatfluvastatinexhibitsmuchgreaterinhibitionofLDLoxidationthanpravastatin 96) .Thisreductioninlipidperoxidationmaycontributetotheabilityofstatinstopreventorreduceatherosclerosis 97) . Nitric oxide (NO), the smallest signaling molecule,isproducedbyNOsynthaseandcontrolsvascular tone 98) .The upregulationofNOformationwithout increases in superoxide production induced by statintreatmentcontributestotheinhibitionoflipid peroxidation.Inadditiontoitsroleasapotentendogenousvasodilator 99) ,NOpossessesanti-inflammatory and antioxidant activities 100) by inhibiting the release of proinflammatory cytokines 101) and the expression ofendothelialcelladhesionmolecules 102) .NOiscatalyzed by a family of NOS enzymes 103) , and statins have been shown in both human studies and animal models to upregulate the NOS-3 expression 104) in a processthatimprovestheendothelialfunction 105, 106) . In studies designed to determine the mechanism of eNOSupregulationinducedbystatins,mevastatinhas beenshowntosignificantlyincreasethelevelsofboth eNOS mRNA and proteins in human endothelial cells 107) . In addition, simvastatin and atorvastatin enhancetheeNOSactivitybyactivatingthephosphatidylinositol 3-kinase/Akt pathway and decreasing caveolin abundance, respectively 108, 109) , and atorvastatin has been reported to reduce the infarct size by increasingtheactivityofiNOS 110) .Hence,statinshave thepotentialtoenhanceNObioavailabilityinthevasculaturebydecreasingsuperoxideproductionandsubsequentNObreakdownaswellasupregulatingNOS.
In addition, atorvastatin has been reported to inhibitplatelet-mediatedLDLoxidationandisoprostane formation 111) . A recent study also demonstrated that atorvastatin therapy acutely reduces oxidative stressbyinhibitingNox2inplatelets 112) ,whilepitavastatinhasbeenreportedtomitigateoxidativestressand reduceelevatedlevelsofROSandNADPHoxidasein high-risk animal models 113, 114) . Furthermore, statins decrease the mRNA expression of NADPH oxidase subunits 11) .Thesedatasuggestthatstatinsexertantioxidant effects by modulating the NADPH-oxidase enzymeactivity.
Statins are also involved in the isoprenylation pathway.Thecardioprotectiveeffectsofstatinsmaybe related to the reduced synthesis of mevalonate, the immediate product of HMG-CoA reductase, rather thanthatofcholesterolitself.Moreover,statinsinhibit the translocation of Rac-1, which is required for the productionofNADPHoxidase,tothemembrane 11, 115) . These effects of statins serve to reduce the oxidative stressburdenonthevasculature.
Atorvastatin and lovastatin increase the productionofcatalaseintheliverandaorticvascularsmooth musclecells 11, 116) .Rosuvastatinisknowntohaveantioxidantpropertiesduetoitsupregulationofglutathione synthesis 117) . In addition, one study showed that pitavastatindirectlyinhibitstheformationofROSin endothelialcells 118) .Therefore,individualstatinsexert distinct antioxidant effects via diverse mechanisms and/ortheiractionsinvariouscellsystems.
Statins have a number of anti-inflammatory effects 5, 119) . For example, they reduce the level of C-reactive protein, a marker of inflammation and an independentpredictorofCVD 4, 120) .Meanwhile,atorvastatin inhibits both proinflammatory cytokine releaseandmonocyteadhesioninresponsetoverylow levels of endotoxin 121) . In general, statin treatment reduces NF-κB activation 122) , inhibits the CD40-CD40ligandexpression 38, 123) anddecreasesthematrix metalloproteinase levels inTHP-1 monocytes 124) and humancarotidplaques 125) ,whiletreatmentwithrosuvastatin, atorvastatin and/or simvastatin increases the HDL-cholesterollevel 126) ,whichhasbothantioxidant andanti-inflammatoryproperties.TheseHDL-raising effectsofstatinsmayalsorelieveoxidativestress.
Effects of Statins on Fatty Liver
AlthoughtheeffectsofstatinsonthepathogenesisofNAFLDhasnotyetbeenclarified,manystudies have demonstrated the beneficial role of statins in treating NAFLD. In a study with a small number of patients, a significant reduction of hepatic steatosis wasnotedamongthesubjectstakingstatinscompared to that observed in those not taking statins 127) . Furthermore,studiesofvariousstatinshavedemonstrated reductions in the levels of aminotransferases and hepatic lipids [128] [129] [130] . However, one small pilot study comparing simvastatin monotherapy with non-statin treatmentfoundnosignificantreductionsintheaminotransferaselevels,degreeofhepaticsteatosis,inflammatoryactivityorfibrosis,despitea26%reductionin theLDLlevelassociatedwithstatinuse 131) .Incontrast, rosuvastatinandpitavastatintreatmenthasbeenshown to improve metabolic parameters and liver histology inpatientswithfattyliveranddyslipidemia 132, 133) . 
.Thisdrugalsoimprovestheprognosisof hepatic fibrosis by increasing the eNOS expression and decreasing the iNOS expression in an animal modeloffattyliver 135) .Becauseoxidativestressisone ofthemaincausativefactorsunderlyingthepathogenesis of NAFLD 23) , statins appear to play a protective roleagainsttheprogressionofNAFLDviatheirantioxidantproperties.
Statinsarealsoeffectiveinreducingthelevelsof biomarkers, such as TNFα, IL6 and C-reactive protein,whichareindicativeofanadvancedhistologyof NASH 136) . Atorvastatin improves the disease activity viaitsTNFα-loweringeffectsinbiopsy-provenNASH patients 137) , and rosuvastatin significantly ameliorates hepatic lobular inflammation by decreasing the hepaticmRNAexpressionofTNFαandIL6 138) . Some statins increase the adiponectin level, whichmaydecreaseFFAdeliverytotheliverandthus slowtheprogressionofsteatosis 128, 139) .Arecentstudy demonstrated that atorvastatin therapy prevents dietinducedlipidaccumulationintheliveringuineapigs via the downregulation of hepatic CD36 proteins, which subsequently facilitates the hepatic uptake of lipids 140) . In a diet-induced fatty liver animal model, rosuvastatin was found to ameliorate hepatic fibrosis in association with a decrease in the hepatic mRNA expressionofTGF-β,connectivetissuegrowthfactor andtype-1procollagen 138) . Therefore,bothinvitroandinvivostudiessuggestthatstatinsplayaprotectiveroleinthedevelopmentandprogressionofNAFLDviavariousmechanisms. However, further mechanistic studies are warrantedtoclarifytheexactrolesofstatinsinthisfield.
Association between Statin Treatment and the Progression of Insulin Resistance and T2DM
Althoughstatinshavebeenproventobeeffective inreducingCVD,conflictingdataexistregardingthe effects of some statins on the risk of incident T2DM 91, 141, 142) .Interestingly,ameta-analysisofrandomized controlled trials suggested potential differences between individual statins, with pravastatin showingatrendtowardreducingmetabolicrisksand atorvastatin, rosuvastatin and simvastatin together being associated with a significantly increased risk of T2DM vs. a placebo 89) . More recent analyses have demonstrated an increased incidence of diabetes followingstatintreatment,regardlessofthestatintype 91, 142) . Highdosesofstatinsreducetheriskofcardiovascular events,althoughtheyalsotendtoincreasetheriskof T2DM 91) . The mechanisms by which statins increase the risk ofT2DM have not been fully elucidated. However, statins may decrease the production of metabolitesofHMG-CoA,suchasisoprenoids,whichupregulate insulin-responsive glucose transporter (GLUT)-4, thereby enhancing glucose uptake 143) . Lovastatin, atorvastatin and simvastatin decrease isoprenoid synthesis and downregulate GLUT-4 production, thus inducingareductionininsulinsensitivity 92, 143, 144) .
Effects of Individual Statins on the Adiponectin Levels
Adiponectin,aninsulinsensitizingadipocytokine linkedtotheredoxsystem,mayhaveaneffectonthe statin-adiponectin-insulin resistance relationship. For example, treatment with the globular domain of human adiponectin suppresses glucose-induced ROS inadose-dependentmannerupto81% 145) .Inanin vitrostudy,treatmentofendothelialcellswithhuman adiponectin inhibited the release of oxidized LDLinduced superoxide, indicating that adiponectin suppressescellularsuperoxidegeneration,possiblyviaan NAD(P)Hoxidase-linkedmechanism 146) . Individual statins may have different effects on thecirculatingand/orexpressionlevelsofadiponectin. Statins that increase adiponectin may have beneficial metaboliceffects,suchasimprovementsinthevascular actions of insulin, decreases in inflammation and reductions in endothelin-1 secretion in the endothelium. For example, pravastatin and pitavastatin both improve insulin sensitivity by increasing the circulating adiponectin levels in humans 147, 148) . In contrast, other statins, particularly when administered at high doses,resultinunfavorableeffects,suchasreductions in insulin secretion and the exacerbation of insulin resistance 143) . For example, in one study, the blood glucoselevels,asdeterminedonoralglucosetolerance tests, were higher in the group treated with atorvastatin for six weeks than in the control group 144) . In another study, simvastatin (20 mg) treatment significantly decreased the plasma adiponectin levels and insulinsensitivity,whilepravastatin(40mg)treatment significantly increased the plasma adiponectin levels andinsulinsensitivityatequallipid-loweringdoses 148) . In contrast, neutral effects of pitavastatin on glucose homeostasiswereobservedintwocohortsofsubjects withmetabolicsyndrome,independentoftheefficacy of this drug in reducing LDL 149) . Most recently, the J-PREDICTstudyshowedthatpitavastatintreatment reduces the incidence ofT2DM in Japanese subjects with prediabetes by 18% over three years (Odawara M, Pitavastatin and incident T2DM; 5 th Scientific MeetingoftheAsianAssociationfortheStudyofDiabetes, 2013, Seoul, Korea). Therefore, differences in the metabolic actions of individual statins may be mediatedbyadiponectin,whichisimplicatedinROS productionandoxidativestress.Therefore,theriskof inducing insulin resistance and benefits in reducing cardiovascular risks should be considered in an integratedfashion 7, 150) .
Conclusions
Theworldwideobesityepidemicisdrivingenormous increases in the incidence of cardiometabolic disorders. Along with insulin resistance, atherogenic dyslipidemia, endothelial dysfunction, activation of the renin-angiotensin system, endoplasmic reticulum stress and dysregulation of the redox system with resultinglow-gradeinflammationappeartoplayarole in the development of cardiometabolic disorders. There is now compelling evidence that statins have the ability to prevent dysregulation of the redox system by reducing the oxidative stress that contributes to these conditions.Therefore, further studies focusingontheeffectsofstatinsbeyondtheirLDL-loweringactionsareclearlywarranted.
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